Compare VMD & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | DMAC |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.4M | 441.6M |
| IPO Year | N/A | N/A |
| Metric | VMD | DMAC |
|---|---|---|
| Price | $7.34 | $8.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 158.9K | ★ 584.7K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.92 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $254,794,000.00 | N/A |
| Revenue This Year | $20.05 | N/A |
| Revenue Next Year | $17.44 | N/A |
| P/E Ratio | $21.85 | ★ N/A |
| Revenue Growth | ★ 18.89 | N/A |
| 52 Week Low | $5.93 | $3.19 |
| 52 Week High | $8.62 | $10.42 |
| Indicator | VMD | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 54.27 |
| Support Level | $7.31 | $8.00 |
| Resistance Level | $7.68 | $8.73 |
| Average True Range (ATR) | 0.20 | 0.67 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 69.77 | 27.24 |
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.